(CMPS) – Company Press Releases
-
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
-
Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights
-
Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved
-
Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement
-
Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder
-
Compass Pathways appoints Teri Loxam as Chief Financial Officer
-
Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry
-
Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center
-
COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights
-
COMPASS Pathways announces CFO transition
-
COMPASS Pathways appoints Daphne Karydas to its Board of Directors
-
COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression
-
COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors
-
COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights
-
First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine
-
COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmac
-
Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybin
-
American Medical Association Releases Language of First New Current Procedural Terminology Code for Psychedelic Therapies
-
COMPASS Pathways' key patents upheld by the US Patent and Trademark Office
-
COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer
-
Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part of large phase 3 study
-
Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023
-
COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights
-
American Medical Association to Issue First New Code for Psychedelic Therapies
-
American Medical Association to Issue First New Code for Psychedelic Therapies
-
COMPASS Pathways to participate in upcoming 22nd Annual Needham Virtual Healthcare Conference
-
COMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care Conference, Oppenheimer 33rd Annual Healthcare Conference, and Loop Capital Investor Conference
-
COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
-
COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
-
COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial results on 28 February 2023
-
COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP
-
COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP
-
COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx Conference
-
COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights
-
COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights
-
COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine
-
One Mind Announces the Winners of the 2022 Rising Star Awards for Mental Health Research
-
COMPASS Pathways plc announces second quarter 2022 financial results and business highlights
-
COMPASS Pathways plc announces second quarter 2022 financial results and business highlights
-
COMPASS Pathways Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)
-
COMPASS Pathways Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)
-
COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
-
COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
-
COMPASS Pathways plc to announce second quarter 2022 financial results on 4 August 2022
-
COMPASS Pathways plc to announce second quarter 2022 financial results on 4 August 2022
-
COMPASS Pathways appoints Kabir Nath as Chief Executive Officer
-
COMPASS Pathways appoints Kabir Nath as Chief Executive Officer
-
COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting
-
COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting
-
COMPASS Pathways to participate in upcoming Citi’s Biopharma Virtual Co-Panel Day and H.C. Wainwright Global Investment Conference
Back to CMPS Stock Lookup
